Pre-made Larcaviximab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-297
Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Larcaviximab is a chimeric (mouse/human) monoclonal antibody that can be potentially used in the treatment of Ebola Virus Infection.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Larcaviximab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody|
|Target||Zaire Ebolavirus GP|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||5ken:CD:GH:NO|
|95-98% SI Structure||None|
|Companies||Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases|
|Conditions Active||Ebola virus infections|
|Development Tech||Zmapp Technology|